NanoViricides, Inc. said that fresh biological rhythm tests and data breakdown have shown that animals treated with its lead anti-HIV drug candidate, HIVCide-I, demonstrated a substantially greater reduction in viral load -- number of toxic virus particles per milliliter of blood -- when compared to the animals given the anti-HIV "combo cocktail" in a preliminary animal study. An historic objective of anti-HIV regimen is to minimize the viral load.

More: - Continued here